Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.202 SEK | -1.70% | -5.39% | -97.98% |
May. 02 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
Apr. 22 | Transcript : Xbrane Biopharma AB - Special Call |
Sales 2024 * | 344M 31.77M | Sales 2025 * | 680M 62.9M | Capitalization | 309M 28.57M |
---|---|---|---|---|---|
Net income 2024 * | -186M -17.2M | Net income 2025 * | 104M 9.62M | EV / Sales 2024 * | 0.82 x |
Net cash position 2024 * | 28.17M 2.6M | Net Debt 2025 * | 116M 10.7M | EV / Sales 2025 * | 0.62 x |
P/E ratio 2024 * |
-1.5
x | P/E ratio 2025 * |
4.22
x | Employees | 93 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.26% |
Latest transcript on Xbrane Biopharma AB
1 day | -1.70% | ||
1 week | -5.39% | ||
Current month | -6.70% | ||
1 month | -29.37% | ||
3 months | -86.75% | ||
6 months | -99.15% | ||
Current year | -97.98% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 14-12-31 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 21-01-10 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 17-10-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 14-12-31 | |
Director/Board Member | 70 | 14-12-31 | |
Director/Board Member | 53 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 0.202 | -1.70% | 12,159,090 |
24-05-02 | 0.2055 | -5.08% | 8,340,380 |
24-04-30 | 0.2165 | +4.09% | 5,244,928 |
24-04-29 | 0.208 | -2.58% | 12,043,920 |
24-04-26 | 0.2135 | -1.39% | 11,591,000 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.98% | 28.6M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- XBRANE Stock